未登录

P

Perrine Créquit

Nantes Universite

H指数:17

被引数:1,183

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients

CLINICAL LUNG CANCER

IF3.3

2024-03-014

OAAI

A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensivestage small cell lung cancer (ES-SCLC) patients

ANNALS OF ONCOLOGY

IF65.4

2023-10-010

PRE

Prospective Radiologic-Pathologic Correlation of Macroscopic Volume and Microscopic Extension of Nonsolid Lung Nodules on Thin-section CT Images for Sublobar Resection and Stereotactic Radiotherapy Planning

CLINICAL LUNG CANCER

IF3.3

2023-03-010

PRE

Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review

IF8.3

2021-04-0812

OAAI

Published trials of TACE for HCC are often not registered and subject to outcome reporting bias

IF7.5

2021-02-013

OAAI

Future of evidence ecosystem series: 3. From an evidence synthesis ecosystem to an evidence ecosystem

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2020-07-0140

OAAI

Future of evidence ecosystem series: 1. Introduction Evidence synthesis ecosystem needs dramatic change

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2020-07-0136

OAAI

Future of evidence ecosystem series: 2. current opportunities and need for better tools and methods

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2020-07-0126

OAAI

Accuracy in detecting inadequate research reporting by early career peer reviewers using an online CONSORT-based peer-review tool (COBPeer) versus the usual peer-review process: a cross-sectional diagnostic study

IF8.3

2019-11-1924

OAAI

Automatic screening using word embeddings achieved high sensitivity and workload reduction for updating living network meta-analyses

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2019-04-0117

OAAI

Living network meta-analysis was feasible when considering the pace of evidence generation

JOURNAL OF CLINICAL EPIDEMIOLOGY

IF5.2

2019-04-0114

PREAI

Use of Late-Life Expectancy for Assessing the Long-Term Benefit of Immune Checkpoint Inhibitors

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2019-01-048

OAAI

Benefit of immune checkpoint inhibitors (ICIs) for second-line treatment of advanced non-small cell lung cancer (NSCLC) using restricted mean survival time (RMST).

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-11-190

PRE

Effect of cannabis and tobacco on emphysema in patients with spontaneous pneumothorax

DIAGNOSTIC AND INTERVENTIONAL IMAGING

IF8.1

2018-07-0117

PREAI

Avoidable waste of research related to outcome planning and reporting in clinical trials

临床试验中与结果计划和报告相关的研究可避免的浪费

IF8.3

2018-06-1139

OAAI

Mapping of Crowdsourcing in Health: Systematic Review

健康众包的映射: 系统综述

JOURNAL OF MEDICAL INTERNET RESEARCH

IF6

2018-05-1596

OAAI

Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates

IF3.1

2018-02-2017

PREAI

Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network metaanalysis

表皮生长因子受体野生型或未知状态的晚期非小细胞肺癌二线治疗的疗效和安全性比较: 系统评价和网络荟萃分析

IF8.3

2017-10-3032

OAAI

Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015

ANNALS OF ONCOLOGY

IF65.4

2017-05-0197

OAAI

PD-L1 expression and tumor immune-cell infiltration in non-small cell lung cancer from HIV-infected patients

ANNALS OF ONCOLOGY

IF65.4

2016-10-010

OAAI